Sources indicate that ocular Therapeutix, Inc. (OCUL) UBS Global Biopharma Conference 2026 November 17, 2026 7:00 AM EST.

Pravin Dugel - Executive Chairman, President & CEO.

Alice Nettleton - UBS Investment Bank, Research Division.

Alice NettletonUBS Investment Bank, Research Division.

Industry observers note that good morning, everybody. Welcome to the next session at the UBS Biopharma Conference in London. I'm Alice Nettleton, one of the U.S. SMID biotech analysts at UBS. Happy to introduce Ocular Therapeutix. With us today is Pravin Dugel, CEO. Thank you so much, Pravin, for joining us. Good to see you.

Pravin DugelExecutive Chairman, President & CEO.

According to recent reports, and Alice, thanks for having me. I appreciate your invitation to be here.

Alice NettletonUBS Investment Bank, Research Division.

It has been revealed that absolutely. So maybe just to level set for the audience, for people who are less familiar with the Ocular story, could you give a quick overview? And then we can move to some Q&A.

Pravin DugelExecutive Chairman, President & CEO.

Sources indicate that sure. So the organization is called Ocular Therapeutix. We have a drug that has successfully completed a Phase III study. We have been able to show superiority versus an anti-VEGF for the first time ever. We have a result that has a very robust p-value of less than 0.0006, and we're getting ready to submit for approval this quarter. We are on track to do that. The drug is called AXPAXLI. It's a TKI. We believe that we'll be the first and only proper maintenance drug. We have shown in this trial that this drug will last for a year in most patients. And unlike the other drugs that you know about that are bolus injections, and there's a lot of them, whether they be generic or premium drugs, we believe that our drug will be the first drug that will be approved as a true maintenance drug.

→ Read original article